Experts believe a wider spat with Europe would be much more damaging than the current tit-for-tat with China.Traderead more
After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Markets pay particular attention to Italy's spending, given its public debt pile. This stands at above 130% of its growth rate, one of the highest in the world.Politicsread more
Flight bookings to Hong Kong have fallen 10%, hit by the unrest in the city, said Alan Joyce, the chief executive of Australian carrier Qantas Airways.Airlinesread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
These in-demand skills can command top pay packets, says Feon Ang of professional networking site LinkedIn.Get Aheadread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
Illumina shares shed nearly 25 percent Tuesday after the San Diego-based biotech company trimmed its third-quarter revenue estimates.
The shortfall was due to a decline in demand for its high-speed genetic sequencing instruments used to analyze large genomes, the company said.
Illumina now expects to report revenue of about $607 million, which is about 10 percent higher than last year's third-quarter revenue of $550 million. Previously, the company expected to report revenue in the range of $625 million to $630 million.
Based on current trends, the company said it expects its fourth-quarter revenue will be flat to slightly up sequentially.
Shares of Pacific Biosciences of California, another biotechnology company focused on genetic sequencing, dropped 5.8 percent Tuesday morning.
The key biotechnology ETF declined 3.8 percent Tuesday.
Illumina's shares closed at $184.85 on Monday before the the company released the third-quarter revenue forecast.